Sign up Australia
Proactive Investors - Run By Investors For Investors

Imugene’s shares surge higher following early promise in gastric cancer trial

The company is well funded with a cash balance of circa $12 million as at 31 December 2017.
Imugene’s shares surge higher following early promise in gastric cancer trial
The vaccine induced strong immune responses in patients with metastatic gastric cancer

Imugene Limited’s (ASX:IMU) shares are trading circa 21% higher intra-day at $0.017 following early promise in gastric cancer clinical trial for its HER-Vaxx cancer vaccine (IMU-131).

HER-Vaxx is a next generation HER2 cancer therapy using B cell peptides, which harness the body’s ability to develop antibodies against the disease.

Imugene’s latest clinical results indicate that IMU-131 induces strong immune responses in patients with metastatic gastric cancer, with antibodies to the target cancer biomarker strongly evident in validated assays.

Importantly, clinicians have reported no safety, toxicity or tolerability issues with HER-Vaxx during the first cohort dosing of patients.

Dose escalation recommended

The cohort review committee for the study has reviewed the results and has recommended dose escalation.

The clinicians at eight sites across Hong Kong, Taiwan and Thailand will determine if the administration of HER-Vaxx in combination with chemotherapy will prolong survival, delay tumour progression, or reduce the tumour burden in patients with metastatic gastric cancer.

Multi-billion dollar market

HER-Vaxx works by targeting the same receptor as Herceptin and Perjeta, two leading antibody drugs marketed by Roche, with annual sales of US$8.2 billion.

Unlike Herceptin and Perjeta, which are “injected synthetic antibody” products, HER-Vaxx activates the patient’s own immune system to produce a continuous supply of cancer targeting antibodies and induce a response against the tumours.

The early clinical data for HER-Vaxx is encouraging, indicating immune activation in vaccinated patients in a manner that is consistent with the vaccine’s postulated mechanism of action.

View full IMU profile View Profile

Imugene Timeline

Newswire
October 19 2016

Related Articles

1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
lupus poster
January 18 2018
The last of the 200 patients has had their final assessment and the data is now being processed and analysed
affimer technology
May 01 2018
The company is making progress with its lead immuno-oncology programmes

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use